Evidence map›Paper›PMID 40952411›Full record

ReviewPharmacogenomics

Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease.

Anmol Kanda, Anjna Rani, Avijit Mazumder

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacogenomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anmol KandaDepartment of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India.ORCID 0000-0003-1922-2909
Anjna RaniDepartment of Pharmaceutical Science, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India.
Avijit MazumderDepartment of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease (AD) represents a formidable challenge in neurology, characterized by progressive neurodegeneration and cognitive decline. Traditional therapeutic approaches have failed to deliver significant outcomes, underscoring the need for innovative paradigms such as precision medicine. The review explores integrating genomic, biomarker-driven, and individualized therapeutic strategies to tackle AD. It examines the role of key genetic factors, including

Indexed as

Alzheimer DiseasePrecision MedicineApolipoproteins EBiomarkersGenetic Predisposition to DiseaseHumansMethylenetetrahydrofolate Reductase (NADPH2)Apolipoproteins EBiomarkersMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanAlzheimer’s diseasebiomarkersneurologypatent technologiesprecision medicine

Identifiers

PMID40952411
PMCPMC12582071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.